Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
Options
BORIS DOI
Date of Publication
2012
Publication Type
Article
Division/Institute
Author
Meyrat, P | |
Schoepfer, A M |
Subject(s)
Series
Alimentary pharmacology & therapeutics
ISSN or ISBN (if monograph)
0269-2813
Publisher
Wiley-Blackwell
Language
English
Publisher DOI
PubMed ID
23066911
Description
While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| Meyrat AlimentPharmacolTher 2012.pdf | text | Adobe PDF | 359.62 KB | publisher | published |